loader2
Partner With Us NRI
IPOLogoImage

Emcure Pharmaceuticals IPO

14,112
Minimum Investment

Price Range (₹)

Rs. 960 –Rs. 1008

Issue Size (₹ in Cr.)

Up to 1952.03 Cr

Minimum Quantity

14 Shares

Bidding Period

Jul 3 – Jul 5, 2024
Pre- Apply

Emcure Pharmaceuticals IPO Issue timeline

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

About the Emcure Pharmaceuticals IPO

- One of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas
- Research and development (“R&D”) driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics
- The 13th largest pharmaceutical company in India in terms of Domestic Sales for MAT September 2023
- The largest pharmaceutical company in the gynecology and human immunodeficiency virus (“HIV”) antivirals therapeutic areas in India in terms of Domestic Sales for MAT September 2023 (Source: CRISIL Report)

Read More

Strengths

Well-placed to Leverage Leading Position in the Domestic Market

They are focused on the domestic market, with sales in India contributing to 50.84% and 53.16% of their total revenue from operations for the six months ended Sep 30, 2023 and the FY23, respectively. Their strong position in a number of therapeutic areas such as gynecology, cardiovascular, blood-related, pain and analgesics and oncology/anti-neoplastics has been driven by differentiated product portfolio and first to market product launches (source: Company DRHP)

Demonstrated Capabilities of Building Brands

They have demonstrated strong capabilities and a proven track record in building brands. Eight of their brands were ranked among the 300 highest selling brands in the IPM, in terms of Domestic Sales for MAT Sep 2023.Further, between MAT Sep 2019 and MAT Sep 2023, the volumes of their brands with sales of more than ₹250 million grew by 2.51%, as compared to the IPM brands with sales of more than ₹250 million, which grew by 0.38% (Source: CRISIL Report)

Extensive and Diversified Manufacturing Capacity

They have 13 manufacturing facilities across the states of Maharashtra, Gujarat, Sikkim and Karnataka and the union territory of Jammu and Kashmir, in India. Relying on their in-house capabilities rather than outsourcing manufacturing for their specialty products allows us to better ensure product quality as well as optimize costs (Source: Company DRHP)

Risks

There are outstanding legal proceedings involving their company, directors, promoters, subsidiaries and their group company, Heritage

There are outstanding legal proceedings involving company, directors, promoters and their subsidiaries. These proceedings are pending at different levels of adjudication before various courts, tribunals and arbitrators, from which further liability may arise. There is one civil case outstanding against their Group Company, Heritage, the outcome of which could have a material impact on their company. (Source: Company DRHP)

Manufacturing and research and development operations are subject to operational risks

Their business is dependent on the ability to manage manufacturing and R&D facilities, which are subject to various operating risks and factors outside their control. Inability to effectively respond to any such shutdown or slowdown, could result in them being unable to satisfy their contractual commitments, which could have an adverse effect on their business (Source: Company DRHP)

Financials

  • Net Worth
  • Total Borrowings
  • Profit for the period
  • Earning Per Share

Industry Trends

- Global pharmaceutical market to grow at steady 4.5-5% CAGR from 2022 to 2027 : Global pharmaceutical market has grown at a CAGR of 5% from approximately US$1,135 billion in CY17 to approximately US$1,457 billion in CY22. After showing strong growth in CY21 and 22 on account of pent-up demand, the market is expected to moderate in the CY23. However, It is expected to sustain 4.5-5% CAGR growth over the next five years from 2022 to 2027 to reach approximately US$1,750 to US$1,800 billion in CY27

 

- Biopharmaceutical industry share to touch approximately 35-37% globally by 2027: The global biopharma industry has significantly outperformed the conventional pharmaceuticals segment over the past few years.CRISIL expects the performance of the biopharma segment to continue, primarily driven by the biologics segment although there is expected to be some moderation in growth owing to the biosimilar launches in the regulated markets.

Subscription Status

Retail Individual Investor
Non-Institutional Investor
Qualified Institutional Buyers
Employee
Overall

Why invest in IPO through ICICIdirect

Paperless

Applications

Hassle-free

refunds

Convenient investments

within a few clicks
Multiple modes

of application

Follow 3 simple steps TO APPLY IPO

  • Directly from Bank A/c

    For ICICI Bank linked A/c

  • Using UPI

    For non ICICI Bank A/c

  • lock-in of 3 years
    Select IPO

    Go to the IPO section, select the IPO you want to apply from the list and click on ‘Apply’.

  • lock-in of 3 years
    Fill in the required details

    Fill in the quantity of the number of shares you want to buy. To apply at maximum price, check the cut-off price box and amount is auto calculated. If you want to apply at some other price within the price band, then you can enter the price manually by clicking on “Add bid” option.

  • lock-in of 3 years
    Confirm your request

    Click on proceed to confirm the order. You can view the placed order under “order book”.

stepstoapplyiponew1
stepstoapplyiponew2
stepstoapplyiponew3
  • lock-in of 3 years
    Select IPO

    Choose the IPO you want to apply from the list. Click on Apply.

  • lock-in of 3 years
    Fill in the required details

    Fill in the quantity of shares. To apply at maximum price, check the cut-off price box and amount is auto calculated. If you want to apply at some other price within the price band, then you can enter the price manually by clicking on “Add bid” option.

  • lock-in of 3 years
    Confirm your request

    Check the A/C, UPI details and click on proceed. You will get an UPI link by which payment can be made.

stepstoapplyiponew1
stepstoapplyiponew5
stepstoapplyiponew4

Features & Benefits ICICIdirect

Trusted by

75 lakh+

customers

45+

Investments & Liability Products

One Click

Investment Basket

Access to

Award-winning

Emcure Pharmaceuticals IPO FAQs

The lot size is 14 shares and minimum investment required is Rs.14,112 for Emcure Pharma IPO

Emcure Pharmaceuticals IPO is mainboard IPO of issue size up to Rs.1952.03 Crores

Emcure Pharmaceuticals IPO issue dates are from 03rd – 05th July, 2024.

The allotment date is 08th July, 2024 and listing date is 10th July, 2024 for Emucre Pharma IPO

Head to IPO section on ICICI Direct website and select Emcure Pharmaceuticals IPO. Enter and submit bid details and then click on proceed to apply once details are verified. It’s that simple!!

The price band of Emcure Pharma IPO is Rs.960 – Rs.1008.

The book runners for the Bharti Hexacom IPO are Kotak Mahindra Capital Company Ltd, Axis Capital Ltd, J.P. Morgan India Private Ltd,Jefferies India Private Ltd

The objectives of Emcure Pharma IPO are Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the company and General corporate purposes

Download App

Download Our App

Play Store App Store
market app
 

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.